Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Controversial roles for dexamethasone in glioblastoma - Opportunities for novel vascular targeting therapies.

Dubinski D, Hattingen E, Senft C, Seifert V, Peters KG, Reiss Y, Devraj K, Plate KH.

J Cereb Blood Flow Metab. 2019 Aug;39(8):1460-1468. doi: 10.1177/0271678X19859847. Epub 2019 Jun 25.

PMID:
31238763
2.

Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP.

Souma T, Thomson BR, Heinen S, Carota IA, Yamaguchi S, Onay T, Liu P, Ghosh AK, Li C, Eremina V, Hong YK, Economides AN, Vestweber D, Peters KG, Jin J, Quaggin SE.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1298-1303. doi: 10.1073/pnas.1714446115. Epub 2018 Jan 22.

3.

Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema.

Campochiaro PA, Peters KG.

Curr Diab Rep. 2016 Dec;16(12):126. Review.

PMID:
27778249
4.

Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling.

Gurnik S, Devraj K, Macas J, Yamaji M, Starke J, Scholz A, Sommer K, Di Tacchio M, Vutukuri R, Beck H, Mittelbronn M, Foerch C, Pfeilschifter W, Liebner S, Peters KG, Plate KH, Reiss Y.

Acta Neuropathol. 2016 May;131(5):753-73. doi: 10.1007/s00401-016-1551-3. Epub 2016 Mar 1.

5.

Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature.

Shen J, Frye M, Lee BL, Reinardy JL, McClung JM, Ding K, Kojima M, Xia H, Seidel C, Lima e Silva R, Dong A, Hackett SF, Wang J, Howard BW, Vestweber D, Kontos CD, Peters KG, Campochiaro PA.

J Clin Invest. 2014 Oct;124(10):4564-76. doi: 10.1172/JCI74527. Epub 2014 Sep 2.

6.

Targeting protein tyrosine phosphatase to enhance insulin action for the potential treatment of diabetes.

Kasibhatla B, Wos J, Peters KG.

Curr Opin Investig Drugs. 2007 Oct;8(10):805-13. Review.

PMID:
17907056
7.

Engineering the catalytic domain of human protein tyrosine phosphatase beta for structure-based drug discovery.

Evdokimov AG, Pokross M, Walter R, Mekel M, Cox B, Li C, Bechard R, Genbauffe F, Andrews R, Diven C, Howard B, Rastogi V, Gray J, Maier M, Peters KG.

Acta Crystallogr D Biol Crystallogr. 2006 Dec;62(Pt 12):1435-45. Epub 2006 Nov 23.

PMID:
17139078
8.

Design and synthesis of potent, non-peptidic inhibitors of HPTPbeta.

Amarasinghe KK, Evdokimov AG, Xu K, Clark CM, Maier MB, Srivastava A, Colson AO, Gerwe GS, Stake GE, Howard BW, Pokross ME, Gray JL, Peters KG.

Bioorg Med Chem Lett. 2006 Aug 15;16(16):4252-6. Epub 2006 Jun 12. Erratum in: Bioorg Med Chem Lett. 2008 Aug 15;18(16):4745.. Evidokimov, Artem G [corrected to Evdokimov, Artem G].

PMID:
16759857
9.

Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: support for an endothelium-dependent mechanism.

Carr AN, Howard BW, Yang HT, Eby-Wilkens E, Loos P, Varbanov A, Qu A, DeMuth JP, Davis MG, Proia A, Terjung RL, Peters KG.

Cardiovasc Res. 2006 Mar 1;69(4):925-35. Epub 2006 Jan 10.

PMID:
16409996
10.

1,2,3,4-Tetrahydroisoquinolinyl sulfamic acids as phosphatase PTP1B inhibitors.

Klopfenstein SR, Evdokimov AG, Colson AO, Fairweather NT, Neuman JJ, Maier MB, Gray JL, Gerwe GS, Stake GE, Howard BW, Farmer JA, Pokross ME, Downs TR, Kasibhatla B, Peters KG.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1574-8. Epub 2006 Jan 4.

PMID:
16386905
11.

A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.

Winter CL, Lange JS, Davis MG, Gerwe GS, Downs TR, Peters KG, Kasibhatla B.

Exp Biol Med (Maywood). 2005 Mar;230(3):207-16.

PMID:
15734724
12.

Tyrosine phosphatases in vessel wall signaling.

Kappert K, Peters KG, Böhmer FD, Ostman A.

Cardiovasc Res. 2005 Feb 15;65(3):587-98. Review.

PMID:
15664385
13.

Preclinical models of human peripheral arterial occlusive disease: implications for investigation of therapeutic agents.

Waters RE, Terjung RL, Peters KG, Annex BH.

J Appl Physiol (1985). 2004 Aug;97(2):773-80. Epub 2004 Apr 23. Review.

14.

Neovascularization in intimal hyperplasia is associated with vein graft failure after coronary artery bypass surgery.

Baklanov DV, Peters KG, Seidel AL, Taylor DA, Annex BH.

Vasc Med. 2003;8(3):163-7.

PMID:
14989556
15.

Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease.

Carr AN, Davis MG, Eby-Wilkens E, Howard BW, Towne BA, Dufresne TE, Peters KG.

Am J Physiol Heart Circ Physiol. 2004 Jul;287(1):H268-76. Epub 2004 Feb 26.

16.

Functional significance of Tie2 signaling in the adult vasculature.

Peters KG, Kontos CD, Lin PC, Wong AL, Rao P, Huang L, Dewhirst MW, Sankar S.

Recent Prog Horm Res. 2004;59:51-71. Review.

PMID:
14749497
17.

Proteome analysis of the rat cornea during angiogenesis.

Thompson LJ, Wang F, Proia AD, Peters KG, Jarrold B, Greis KD.

Proteomics. 2003 Nov;3(11):2258-66.

PMID:
14595824
18.

Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component.

Peters KG, Davis MG, Howard BW, Pokross M, Rastogi V, Diven C, Greis KD, Eby-Wilkens E, Maier M, Evdokimov A, Soper S, Genbauffe F.

J Inorg Biochem. 2003 Aug 1;96(2-3):321-30.

PMID:
12888267
19.

Determination of endogenous extracellular signal-regulated protein kinase by microchip capillary electrophoresis.

Starkey DE, Abdelaziez Y, Ahn CH, Tu J, Anderson L, Wehmeyer KR, Izzo NJ, Carr AN, Peters KG, Bao JJ, Halsall HB, Heineman WR.

Anal Biochem. 2003 May 15;316(2):181-91.

PMID:
12711339
20.

1H, 15N, and 13C resonance assignments of low molecular weight human cytoplasmic protein tyrosine phosphatase-A (HCPTP-A).

Rastogi VK, Diven CF, Seabrook GM, Genbauffe FS, Bechard RT, Fandl JP, Peters KG.

J Biomol NMR. 2002 Jul;23(3):251-2. No abstract available.

PMID:
12238601
21.
22.
23.

Multiple growth factors regulate coronary embryonic vasculogenesis.

Tomanek RJ, Zheng W, Peters KG, Lin P, Holifield JS, Suvarna PR.

Dev Dyn. 2001 Jul;221(3):265-73.

24.

Systemically expressed soluble Tie2 inhibits intraocular neovascularization.

Hangai M, Moon YS, Kitaya N, Chan CK, Wu DY, Peters KG, Ryan SJ, Hinton DR.

Hum Gene Ther. 2001 Jul 1;12(10):1311-21.

PMID:
11440624
25.

Regulation of receptor-mediated protein kinase C membrane trafficking by autophosphorylation.

Feng X, Becker KP, Stribling SD, Peters KG, Hannun YA.

J Biol Chem. 2000 Jun 2;275(22):17024-34.

26.

Transmyocardial laser revascularization limits in vivo adenoviral-mediated gene transfer in porcine myocardium.

Hughes GC, Annex BH, Yin B, Pippen AM, Lin P, Kypson AP, Peters KG, Lowe JE, Landolfo KP.

Cardiovasc Res. 1999 Oct;44(1):81-90.

PMID:
10615392
27.

HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity.

Huang L, Sankar S, Lin C, Kontos CD, Schroff AD, Cha EH, Feng SM, Li SF, Yu Z, Van Etten RL, Blanar MA, Peters KG.

J Biol Chem. 1999 Dec 31;274(53):38183-8.

28.

Allelic and locus heterogeneity in inherited venous malformations.

Calvert JT, Riney TJ, Kontos CD, Cha EH, Prieto VG, Shea CR, Berg JN, Nevin NC, Simpson SA, Pasyk KA, Speer MC, Peters KG, Marchuk DA.

Hum Mol Genet. 1999 Jul;8(7):1279-89.

PMID:
10369874
29.

Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia.

Hughes GC, Lowe JE, Kypson AP, St Louis JD, Pippen AM, Peters KG, Coleman RE, DeGrado TR, Donovan CL, Annex BH, Landolfo KP.

Ann Thorac Surg. 1998 Dec;66(6):2029-36.

PMID:
9930489
30.

Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel.

Peters KG.

Circ Res. 1998 Aug 10;83(3):342-3. No abstract available.

PMID:
9710128
31.

Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2.

Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8829-34.

32.

Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt.

Kontos CD, Stauffer TP, Yang WP, York JD, Huang L, Blanar MA, Meyer T, Peters KG.

Mol Cell Biol. 1998 Jul;18(7):4131-40.

33.
34.

Induction and maintenance of increased VEGF protein by chronic motor nerve stimulation in skeletal muscle.

Annex BH, Torgan CE, Lin P, Taylor DA, Thompson MA, Peters KG, Kraus WE.

Am J Physiol. 1998 Mar;274(3):H860-7. doi: 10.1152/ajpheart.1998.274.3.H860.

PMID:
9530197
35.

VEGF enhances pulmonary vasculogenesis and disrupts lung morphogenesis in vivo.

Zeng X, Wert SE, Federici R, Peters KG, Whitsett JA.

Dev Dyn. 1998 Mar;211(3):215-27.

36.

Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis.

Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E.

Br J Cancer. 1998;77(1):51-6.

37.
38.

Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels.

Channon KM, Fulton GJ, Gray JL, Annex BH, Shetty GA, Blazing MA, Peters KG, Hagen PO, George SE.

Cardiovasc Res. 1997 Sep;35(3):505-13.

PMID:
9415295
39.

Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor.

Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG.

Cell Growth Differ. 1998 Jan;9(1):49-58.

40.

Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues.

Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG.

Circ Res. 1997 Oct;81(4):567-74.

PMID:
9314838
41.

Modulation of tissue factor protein expression in experimental venous bypass grafts.

Channon KM, Fulton GJ, Davies MG, Peters KG, Ezekowitz MD, Hagen PO, Annex BH.

Arterioscler Thromb Vasc Biol. 1997 Jul;17(7):1313-9.

PMID:
9261261
42.

Collagen subtypes III and IV expression in human vein graft atherosclerosis.

Denning SM, Channon KM, Peters KG, Oldham HN Jr, Annex BH.

Am J Cardiol. 1996 Sep 15;78(6):691-4.

PMID:
8831411
43.
44.
45.

Meso1, a basic-helix-loop-helix protein involved in mammalian presomitic mesoderm development.

Blanar MA, Crossley PH, Peters KG, Steingrímsson E, Copeland NG, Jenkins NA, Martin GR, Rutter WJ.

Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5870-4.

46.

Sphingolipid-gated Ca2+ release from intracellular stores of endothelial cells is mediated by a novel Ca(2+)-permeable channel.

Kim S, Lakhani V, Costa DJ, Sharara AI, Fitz JG, Huang LW, Peters KG, Kindman LA.

J Biol Chem. 1995 Mar 10;270(10):5266-9.

47.

Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes.

Annex BH, Denning SM, Channon KM, Sketch MH Jr, Stack RS, Morrissey JH, Peters KG.

Circulation. 1995 Feb 1;91(3):619-22.

PMID:
7828284
50.

Signaling molecules that mediate the actions of FGF.

Demo SD, Kikuchi A, Peters KG, MacNicol AM, Muslin AJ, Williams LT.

Princess Takamatsu Symp. 1994;24:243-9. Review.

PMID:
8983079

Supplemental Content

Loading ...
Support Center